EPISODE · Jun 27, 2025 · 10 MIN
Oral anticoagulant drug considerations in Cancer: Dr Tzu-Fei Wang
from CLOT Conversations
Send us Fan MailIn this episode of Clot Conversations, Dr. Tzu-Fei Wang, Ottawa, shares a summary of her presentations at the 2025 ISTH meeting on recent studies on drug interactions in prostate cancer therapy and the use of anticoagulants. Dr Wang also highlights the significance of the WAVe study in assessing dalteparin use without the traditional dose cap in patients over 90 kg. These findings offer reassurance to clinicians prescribing anticoagulation therapy, minimizing previous concerns. The discussion provides optimism for improved cancer care protocols, showcasing safer, more effective anticoagulation practices for patients..Support the showhttps://thrombosiscanada.caRegister today for our upcoming conference on November 7, 2026 in Montreal at https://thrombosiscanada.ca/2026ConferenceTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Embed this episode
What this episode covers
Send us Fan Mail In this episode of Clot Conversations, Dr. Tzu-Fei Wang, Ottawa, shares a summary of her presentations at the 2025 ISTH meeting on recent studies on drug interactions in prostate cancer therapy and the use of anticoagulants. Dr Wang also highlights the significance of the WAVe study in assessing dalteparin use without the traditional dose cap in patients over 90 kg. These findings offer reassurance to clinicians prescribing anticoagulation therapy, minimizing previous concer...
Ready to play
Oral anticoagulant drug considerations in Cancer: Dr Tzu-Fei Wang
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.